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Abstract
OBJECTIVES: Our goal was to investigate the efficacy of balanced forced diuresis in reducing the rate of acute kidney injury (AKI) in cardiac
surgical patients requiring cardiopulmonary bypass (CPB), using the RenalGuardV
R
(RG) system.
METHODS: Patients at risk of developing AKI (history of diabetes and/or anaemia; estimated glomerular filtration rate 20–60 ml/min/1.73
m2; anticipated CPB time >120 min; log EuroSCORE > 5) were randomized to the RG system group (n = 110) or managed according to
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current practice (control = 110). The primary end point was the development of AKI within the first 3 postoperative days as defined by the
RIFLE (Risk, Injury, Failure, Loss of kidney function, End-stage renal disease) criteria.
RESULTS: There were no significant differences in preoperative and intraoperative characteristics between the 2 groups. Postoperative AKI
rates were significantly lower in the RG system group compared to the control group [10% (11/110) vs 20.9% (23/110); P = 0.025]. This ef-
fect persisted even after controlling for a number of potential confounders (odds ratio 2.82, 95% confidence interval 1.20–6.60; P = 0.017)
when assessed by binary logistic regression analysis. The mean volumes of urine produced during surgery and within the first 24 h postop-
eratively were significantly higher in the RG system group (P < 0.001). There were no significant differences in the incidence of blood trans-
fusions, atrial fibrillation and infections and in the median duration of intensive care unit stays between the groups. The number needed to
treat with the RG system to prevent AKI was 9 patients (95% confidence interval 6.0–19.2).
CONCLUSIONS: In patients at risk for AKI who had cardiac surgery with CPB, the RS RG system significantly reduced the incidence of AKI
and can be used safely and reproducibly. Larger studies are required to confirm cost benefits.
Clinical trial registration number: NCT02974946




AKI Acute kidney injury
CICU Cardiac intensive care unit
CPB Cardiopulmonary bypass
i.v Intravenous
KDIGO Kidney Disease: Improving Global Outcomes





Acute kidney injury (AKI) after cardiac surgery is well docu-
mented [1]. Over the last decade, standardization of the defin-
ition of AKI has been achieved with a view to improving
diagnosis, treatment and prevention [2]. Although several strat-
egies have been trialled to reduce AKI [3], it continues to account
for significant morbidity and mortality in patients undergoing
cardiac surgery [1, 4, 5].
The ‘Kidney Disease: Improving Global Outcomes’ (KDIGO)
guidelines for AKI recommended initiation of various supportive
measures (volume management, maintenance of adequate blood
pressure and judicious avoidance of nephrotoxins) in patients at
risk for AKI [6]. Using such strategies in high-risk patients has
been reported to reduce the rate of AKI from 71.1% to 55.1% [7].
The RenalGuardV
R
(RG) system (RenalGuard Solutions Inc.,
Milford, MA, USA) has been reported to reduce AKI in patients at
risk of contrast-induced nephropathy in percutaneous coronary
intervention and transcatheter aortic valve implantation [8–10].
These studies showed that the RG system reduced the incidence
of AKI by 60–75%. The RG system uses forced diuresis with low-
dose (0.25–0.5 mg/kg) furosemide along with administration of
intravenous (i.v.) fluids at a rate that is matched in real time to
the urine output to prevent inadvertent volume depletion.
Forced diuresis with matched rehydration as a protection against
contrast-induced nephropathy has been endorsed in the
European Society of Cardiology guidelines [11].
The various aspects of the RG system have previously been
described [12]. It includes a closed-loop fluid management sys-
tem, high-volume fluid pump, high-accuracy dual weight meas-
uring system, a single-use i.v. set and a urine collection system
that interface with a standard Foley catheter. There are (i) real-
time displays of urine and replacement fluid volumes, (ii) alerts
to drain the urine bag or to replace the hydration fluid bag and
(iii) safety features such as automatic air and occlusion detection.
The console measures the volume of urine in the collection set
(also calculates urine flow rate) and infuses a preset volume of
hydration fluid to match the urine output, as required. The con-
sole allows the user to set the parameters for achieving a net fluid
gain above or loss below the matched hydration. The console
also allows infusion of a bolus of fluid at the user’s request. The
first-in-man assessment of the use of the RG system in patients
having cardiac surgery was described in 2017 [12].
This randomized control trial [the KIDNEY (Kidney protection
using the RenalGuard system in cardiac surgery) study] assessed if
the RenalGuard system reduces the rate of AKI by using balanced




The KIDNEY (Kidney protection using the RenalGuard system in
cardiac surgery) study was reviewed and approved by the institu-
tional research committee (16CARD13) prior to seeking ethical
committee approval (16/NI/0246, 2 December 2016) and was
registered on the ClinicalTrials.gov website (NCT02974946). The
study was also supported by the National Institute of Healthcare
Research, Clinical Research Network, UK (NIHR ID: 32769). All
recruited patients gave written informed consent to partake in
the study. Trial patients were treated according to the
Declaration of Helsinki 2013.
Power calculations
Because there were no studies using the RG system in cardiac
surgery, power calculations were carried out with some assump-
tions. Data from our cardiac surgery database (from 2005 to
2015, around 10 000 patients) and our previous publications [5]
had shown that the rate of AKI in all patients undergoing cardiac
surgery in our institution was around 10% and that the rate of
AKI was just over 40% in patients with (i) diabetes, (ii) an esti-
mated glomerular filtration rate of 20–60 ml/min/1.73 m2, (iii)
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cardiac procedures when CPB time exceeded 120 min, (iv) a
haemoglobin level of 12.5 g/dl or below and (v) a logistic
EuroSCORE of 5 or above. Previous publications describing
patients undergoing percutaneous coronary intervention or
transcatheter aortic valve implantation [8–10] reported an aver-
age reduction in the rate of AKI of 66% when the RG system was
used. Moreover, none of the patients managed with the RG sys-
tem developed AKI after cardiac surgery in a pilot study assessing
safety and feasibility [12]. Thus, for this study, the reduction in the
rate of AKI was estimated at 60%. Allowing for some patients to
be lost to follow-up during the study, 110 patients per group
were deemed adequate to achieve the primary end point with a
power of 0.8 and an alpha of 0.05.
Recruitment and follow-up were completed as suggested in
the Consolidated Standards of Reporting Trials flow diagram
(Fig. 1) from 1 March 2017 to 4 September 2019.
Aims and objectives
The primary aim of the study was to assess the impact of the RG
system on the reduction of AKI (RIFLE—Risk, Injury, Failure, Loss
of kidney function, End-stage renal disease—criteria definition—
50% increase in preoperative ‘baseline’ serum creatinine levels
within the first 3 days after surgery) in patients undergoing car-
diac surgery. The baseline creatinine level was defined as the lat-
est creatinine level available prior to surgery. Secondary
objectives included evaluation of any additional benefits of the
use of the RG system in terms of postoperative complications,
cardiac intensive care unit (CICU) length of stay and early post-
operative creatinine surgical follow-up.
Inclusion criteria
Inclusion criteria included 1 (or more) of the following: (i) dia-
betes (insulin or non-insulin-dependent diabetes mellitus), (ii)
estimated glomerular filtration rate of 20–60 ml/min/1.73 m2, (iii)
cardiac procedures when CPB time was likely to exceed 120 min,
(iv) haemoglobin level of 12.5 g/dl or below and (v) logistic
EuroSCORE of 5 or above (Table 1).
Randomization
Consenting patients were randomized, on the evening prior to
surgery, using a sealed opaque envelope system (devised and
managed by an independent researcher based in the research
and development department). Patients in the RG system group
had the RG system started in the anaesthetic room once the per-
ipheral line and arterial lines were inserted and the patient was
intubated. The RG system ran throughout the cardiac procedure
in the operating room (OR) and for up to 6 h after transfer to the
CICU. Patients were managed at a 0 balance, i.e. volume of urine
output was matched to volume of Hartmann’s fluid replacement
infusion given through the RG system. Forced diuresis was initi-
ated on induction of anaesthesia with a 20-mg i.v. bolus of fur-
osemide aiming for a urine output of at least 200 ml/h, if
possible. If required, the urine output rate was maintained by fur-
osemide infusion that was titrated up to 10 mg/h during the op-
eration The infusion was stopped in the OR at the end of
procedure. In the CICU, the RG system was continued for 6 h
(matching Hartmann’s i.v. infusion rate to the urine output rate).
If the urine output fell below 200 ml/h within the first 6 h after
the patient was admitted to the CICU, an additional bolus of fur-
osemide (20 mg i.v.) was administered. Patients in the control
group were managed according to current medical practice,
which did not include any forced diuresis with i.v. furosemide in
the OR. Otherwise, the management of the patients was similar,
including the anaesthetic technique and the CPB run, including
the need for inotropic support to maintain a mean arterial pres-
sure (MAP) >65 mmHg. The CPB flow was calculated and main-
tained at a cardiac index of 2.4 l/min/m2. Bypass was performed
with mild to moderate (32–34C) hypothermia. The patients
were warmed to a nasopharyngeal temperature of 36.5–37C
and a bladder temperature of >35C prior to discontinuation of
CPB. Both groups of patients were transferred to the CICU
postoperatively.
Statistical analyses
Continuous variables are expressed as mean (standard deviation)
or median (minimum–maximum) for Gaussian and skewed dis-
tributed data, respectively. Group comparisons were carried out
using a two-tailed t-test or the Mann–Whitney U-test according-
ly. Categorical data are expressed as percentages; differences be-
tween the 2 groups were assessed using the v2 test of
independence. The tests were considered significant at P-value
<0.05. The presence (or absence) of AKI was compared using bin-
ary logistic regression (backward elimination) controlled for the
effects of age, gender, ethnicity, study group (RG system or con-
trol), urgency and type of surgery, diabetes, left ventricular func-
tion category, history of renal impairment, preoperative
creatinine level, preoperative estimated glomerular filtration rate,
preoperative haemoglobin level, log EuroSCORE, CPB time,
cross-clamp time, atrial fibrillation postoperatively and blood
transfusions. SPSS version 23.0 (IBM Corp., Armonk, NY, USA)
was used for the statistical analyses.
Two patients who were randomized to the RG system group
could not be catheterized per the urethra at the start of the oper-
ation and needed suprapubic catheter insertion at the end of
procedure and hence were not connected to the RG system.
Additionally, 2 patients in the RG system group and 1 patient
from control group had their surgery cancelled and therefore did
not have postoperative data. All patient data were analysed on
an intention-to-treat basis.
RESULTS
Two hundred and twenty patients were recruited to the study
(110 patients per group). There were no significant differences in
the preoperative and intraoperative patient characteristics (age,
gender, left ventricular function, surgery urgency and type, log
EuroSCORE, creatinine level, e-GFR, haemoglobin level and his-
tory of diabetes, cerebrovascular disease and renal impairment)
between the 2 groups (Table 2). Isolated coronary artery bypass
grafting was performed in 48% of the RG system group and 54%
of the control group. The mean number of grafts was 3.04 and
3.08, respectively (P = 0.79). Isolated valve surgery (aortic valve re-
placement, mitral valve replacement, mitral valve repair) was per-
formed in 14% and 17% of the patients, respectively. Finally,
combined procedures were performed in 38% of the RG system
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procedures included coronary artery bypass grafting, aortic valve
replacement, mitral valve replacement, mitral valve repair, tricus-
pid valve repair, Cox-maze IV atrial fibrillation ablation, aortic
root surgery, ascending aorta replacement, myxoma surgery and
left ventricular aneurysmectomy, in various combinations.
Postoperative AKI rates were significantly lower in the RG sys-
tem group compared to those in the control group [10% (11/
110) vs 20.9% (23/110); P = 0.025]. This effect persisted even after
controlling for potential confounders (odds ratio 2.82, 95% confi-
dence interval 1.20–6.60; P = 0.017) when assessed by binary lo-
gistic regression analysis. Mean volumes of urine produced
during the operation (2366 ± 877 vs 765 ± 549 ml) and within the
first 24 h postoperatively in the CICU (3310 ± 1303 vs 2052 ±
804 ml) were significantly higher in the RG system group
(P < 0.001).
There were no significant differences in the incidence of blood
transfusions (including intraoperative), re-exploration rates for
bleeding, atrial fibrillation rate, infections (chest, surgical site in-
fection, sepsis) and median durations of CICU stays between the
Figure 1: CONSORT flow diagram for recruitment. eGFR: estimated glomerular filtration rate; OPCAB: off-pump coronary artery bypass; RG: RenalGuardV
R
.






Diabetes, n (%) 70 (63.6) 73 (66.4) 0.67
e-GFR <60, n (%) 44 (40) 45 (40.9) 0.89
Anaemia, n (%) 32 (29.1) 34 (30.9) 0.77
Log EuroSCORE >5, n (%) 48 (43.6) 39 (35.5) 0.22
CPB time >120 min, n (%) 41 (38) 44 (40.4) 0.71
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2 groups (Table 3). One patient in the control group required
renal replacement therapy. The MAP and central venous pressure
during surgery and within the first 12-h of CICU admission were
not significantly different (Figs 2 and 3). Inotropic support
(Supplementary Material, Table S1) was used to maintain a MAP
>65 mmHg in 70% of patients in the RG system group and in
77% patients in the control group (P = 0.53). Although only
patients in the study group received i.v. furosemide in the OR
[median dose 28 (0–92) mg], 61% of the study group and 53% of
the control group received i.v. furosemide in the CICU. The me-
dian dose of furosemide used in the CICU was 20 (0–160) mg for
the RG system group and 20 (0–180) mg for the control group
(P = 0.99), within the first 24 h in the CICU. The median in-
hospital stay for both groups was 6 days. The creatinine levels at
various periods are depicted in Fig. 4.
One patient in the RG system group and 2 patients in control
group died prior to hospital discharge. Causes of death were not
related to the use of the device and included cardiogenic shock,
cardiac failure and sepsis (pneumonia), respectively. The number
needed to treat with the RG system to prevent AKI was 9 patients
(95% confidence interval 6.0–19.2). At a median postoperative
follow-up of 8 weeks, most patients had recovered from their AKI
(Table 3).
DISCUSSION
This study confirmed that, in a selected group of patients at risk
for developing AKI post cardiac surgery, the rate of AKI was
reduced when the RG system was used perioperatively.
Given the morbidity and mortality associated with AKI post
cardiac surgery [4, 5, 13], investigative research has ranged from
identifying at-risk patients [14, 15] to using urinary and plasma
biomarkers [7] and goal-directed therapies [16].
This study assessed the potential benefit of the RG system,
which provides both continuous diuresis and balanced
rehydration. The importance of appropriate intravascular volume
management in the prevention of AKI has already been high-
lighted by the KDIGO group [6]. However, the use of furosemide
after cardiac surgery to prevent AKI has been contentious.
Interestingly, as reported by Penk et al. [17], the renal response to
i.v. furosemide can be an indicator of the development of AKI.
They showed that a low urine flow rate after furosemide adminis-
tration was independently associated with AKI. Fakhari et al. [18]
found that continuous infusion of low-dose furosemide in the
perioperative period was beneficial to the kidneys compared to
infusion of 0.9% saline. However, that study was conducted in a
low-risk group (for AKI), and there was no description of the fluid
volume status of the patients. Mahesh et al. [19] confirmed that
the perioperative use of furosemide increased postoperative di-
uresis significantly but did not have an impact on AKI in a high-
risk group (for AKI) of patients. Kunt et al. [20] found that fur-
osemide was beneficial in low-risk (for AKI) patients, whereas
Lassnigg et al. [21] reported that furosemide infusion was detri-
mental. However, patients who received furosemide infusions
had the same volume of i.v. fluid as the placebo group, begging
the question of whether these patients were adequately
rehydrated.
Furosemide may also be beneficial in preventing renal hypoxia
at the level of the loop of Henle whereas forced diuresis prohibits
the buildup of casts within the renal tubules—a process well
known to occur in acute tubular necrosis. Some vasodilatory
effects on renal cortical vessels have also been attributed to fur-
osemide, causing an improvement in renal blood flow [22].
Appropriate fluid management after cardiac surgery is ex-
tremely complex, especially in patients in whom the CPB ma-
chine is used because there are significant volume shifts, and
fluid can be ‘sequestered’ in the extravascular, extracellular space.
This situation leads to a confusing clinical picture of a fluid over-
loaded but an intravascularly volume-depleted patient. Using
diuretics in these patients leads to further intravascular dehydra-
tion, which in turn causes poor organ perfusion and, for the kid-
neys, acute injury. Hence appropriate intravascular rehydration is
vital despite a clinical picture of ‘fluid overload’. There has also
long been a debate regarding the type of fluid used for intravas-
cular rehydration [23, 24]. In this study, Hartmann’s solution (a
mixture of sodium chloride, sodium lactate, potassium and cal-
cium chloride in water) was used for fluid replacement by the RG
system. Although the volumes of urine were significantly higher
in RG system group, this forced diuresis coupled with large vol-
ume rehydration with Hartmann’s solution did not seem to have
impacted the postoperative recovery of the patients because
both groups had similar blood transfusion rates, atrial fibrillation
incidence and infection rates, denoting that the use of the RG
system is safe.
Maintenance of adequate renal perfusion is also important be-
cause the kidneys receive 25% of the cardiac output and produce
180 l of filtrate daily. In its guidelines, the KDIGO AKI working
group suggested the maintenance of adequate arterial perfusion
pressure: 65–90 mmHg [3, 6]. In this study, the organ perfusion
pressure (difference between MAP and central venous pressure)
was maintained throughout the operation and during the stay in
the CICU with inotropic support as required (Figs 2 and 3). There
were no significant differences in the MAP and central venous
pressure between the 2 groups during the period that they were
recorded, namely in the anaesthetic room, prior to initiation of
CPB, 15 min post initiation of CPB, prior to CPB termination,







Agea (years) 67.8 (9.3) 67.0 (9.2) 0.33
BMIa (kg/m2) 29.8 (5.1) 30.7 (5.5) 0.25
Preop haemoglobina (g/l) 135 (16) 134 (18) 0.72
Preop creatininea (mmol/l) 99.0 (28.2) 98.3 (34.7) 0.29
Preop eGFRa (ml/min/1.73 m2) 66.5 (17.2) 68.2 (20.3) 0.47
Logistic EuroSCOREb 3.8 (0.9–67.4) 3.2 (0.9–32.5) 0.3
Male gender, n (%) 87 (79) 84 (76) 0.63
Elective, n (%) 76 (69) 86 (78) 0.13
Non-diabetic, n (%) 30 (27) 30 (27) 0.66
Impaired LVEF, n (%) 51 (46) 38 (34) 0.14
History of CVA, n (%) 11 (10) 8 (7) 0.47
CKD stage >2, n (%) 44 (40) 42 (38) 0.94
Isolated CABG, n (%) 53 (48) 59 (54) 0.41
aDenotes mean (SD).
bDenotes median (minimum–maximum).
BMI: body mass index; CABG: coronary artery bypass surgery; CKD: chronic
kidney disease; CVA: cerebrovascular accident; eGFR: estimated glomerular
filtration rate; LVEF: left ventricular ejection fraction; preop: preoperative;
RG: RenalGuardV
R
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prior to transfer from the OR and within 1, 6 and 12 h of admis-
sion to the CICU (Figs 2 and 3).
There was no significant difference in the median duration of
CICU stays between the 2 groups, it being around 1.2 days for
both groups (27 h for the RG system group and 28 h for the con-
trol group). This result is probably due to the fact that the study
was powered to assess rate of AKI rather than CICU stay. A larger
study would be required to assess this aspect. Other authors of a
large meta-analysis (>300 000 patients) reported a significantly
longer CICU stay when AKI occurred: an average CICU stay of
2.2 days for non-AKI patients compared to 5.4 days for those in
the AKI group [25]. This finding would impact not only the
morbidity of the patient but also the cost of treatment when
AKI develops after cardiac surgery. The cost of managing AKI
post cardiac surgery relates not only to the immediate postoper-
ative phase but also to the long term and to changes in quality
of life.
Table 3: Postoperative data
Intraoperative and postoperative data RG group Control group P-value
CPB timea (min) 120 (56) 114 (46) 0.64
Total urine output in ORa (ml) 2366 (877) 765 (549) <0.001
Urine volume at 6 h in CICUa (ml) 1911 (904) 911 (407) <0.001
Urine volume at 24 h in CICUa (ml) 3310 (1303) 2052 (804) <0.001
Intubation timeb (h) 6 (2–74) 5.5 (2–486) 0.39
CICU stayb (h) 27 (16–410) 28 (8–486) 0.92
Atrial fibrillation, n/total (%) 12/108 (11) 10/108 (9) 0.62
Reexploration, n/total (%) 4/108 (3.6) 1/108 (0.9) 0.4
Blood transfusion, n/total (%) 29/108 (27) 21/109 (19) 0.16
Infection, n/total (%) 10/108 (9) 8/108 (7) 0.59
In-hospital mortality, n/total (%) 1/110 (1) 2/110 (2) 0.56
Primary end point, n/total (%)
AKI rate (RIFLE) 11/110 (10) 23/110 (20.9) 0.025
Follow-up, n/total (%)
AKI at follow-up 1/100 (1) 2/105 (2) 1
Alive at follow-up 104/105 (99) 104/108 (96) 0.37
aDenotes mean (SD).
bDenotes median (minimum–maximum).
Boldface data reflects statistically significant difference between the two groups.
AKI: acute kidney injury; CICU: cardiac intensive care unit; CPB: cardiopulmonary bypass; RIFLE: Risk, Injury, Failure, Loss, End stages of kidney damage; OR: oper-
ating room; RG: RenalGuardV
R
; SD: standard deviation.
Figure 2: MAP (mmHg) at various time intervals for RenalGuardV
R
and control
groups. CPB: cardiopulmonary bypass; ICU: intensive care unit; ICU1: arrival in
ICU; ICU2: in ICU for 6 h; ICU3: in ICU for 12 h; MAP: mean arterial pressure;
On CPB1: on cardiopulmonary bypass for 15 min; On CPB2: prior to stopping
cardiopulmonary bypass; Preop: preoperative; Preop: in anaesthetic room; Pre-
CBP: prior to initiation of cardiopulmonary bypass; Post-CPB: after stopping
cardiopulmonary bypass for 15 min; SD: standard deviation.
Figure 3: Central venous pressure (cm H2O) at various time intervals for the
RenalGuardV
R
system and control groups. CPB: cardiopulmonary bypass; CVP:
central venous pressure; ICU: intensive care unit; ICU1: arrival in ICU; ICU2: in
ICU for 6 h; ICU3: in ICU for 12 h; MAP: mean arterial pressure; On CPB1: on
cardiopulmonary bypass for 15 min; On CPB2: prior to stopping cardiopul-
monary bypass; Preop: preoperative; Preop: in anaesthetic room; Pre-CBP:
prior to initiation of cardiopulmonary bypass; Post-CPB: after stopping cardio-
pulmonary bypass for 15 min; SD: standard deviation.
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Lastly, early postoperative follow-up data suggested that most
patients in this study recovered from their AKI episodes.
However, other reports with longer term follow-up data have
shown that around 20% of patients with AKI after cardiac surgery
may require long-term renal follow-up [5, 26]. Importantly, these
patients also had a poorer quality of life [5, 26, 27].
This study was powered to assess if the use of the RG system
would reduce AKI rates as defined by the RIFLE (Risk, Injury,
Failure, Loss of kidney function, End-stage renal disease) criteria.
It confirmed that the RG system does reduce the rate of AKI and
is safe to use in cardiac surgery in patients at high risk of devel-
oping AKI. A larger, adequately powered randomized control trial
is needed to demonstrate the clinical benefit, such as a reduction
in the ICU stay. Additionally, a cost-benefit analysis needs to be
carried out to justify the use of the device, because the RG system
costs £450 per patient in the UK.
Limitations
The main limitation of this study is that it is a single-centre study.
However, given that the number of patients recruited was deter-
mined by power calculations, the primary outcome was achieved
as per statistical recommendations. Also, because this study was
not blinded, the control group could have been influenced by
some aspects of the Hawthorne effect.
CONCLUSION
In patients at risk for AKI who had cardiac surgery with CPB, the
RG system significantly reduced the incidence of AKI and can be
used safely and reproducibly. Larger studies are required to as-
sess cost benefits.
SUPPLEMENTARY MATERIAL
Supplementary material is available at EJCTS online.
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Acute kidney injury with the RenalGuard system in patients undergoing
transcatheter aortic valve replacement. The PROTECT-TAVI Trial
(PROphylactic effecT of furosEmide-induCed diuresis with matched iso-
tonic intravenous hydraTion in Transcatheter Aortic Valve Implantation).
JACC Cardiovasc Interv 2015;8:1595–604.
[9] Marenzi G, Ferrari C, Marana I, Assanelli E, De Metrio M, Teruzzi G et al.
Prevention of contrast nephropathy by furosemide with matched hydra-
tion the MYTHOS (Induced Diuresis with Matched Hydration Compared
to Standard Hydration for Contrast Induced Nephropathy Prevention)
trial. JACC Cardiovasc Interv 2012;5:90–7.
[10] Briguori C, Visconti G, Focaccio A, Airoldi F, Valgimigli M, Sangiorgi GM
et al.; REMEDIAL II Investigators. Renal insufficiency after contrast media
administration trial II (REMEDIAL II) RenalGuard system in high-risk
patients for contrast-induced acute kidney injury. Circulation 2011;124:
1260–9.
[11] Windecker S, Kohl P, Alfonso F, Collet JP, Cremer J, Falk V et al. 2014
ESC/EACTS guidelines on myocardial revascularization: the task force on
myocardial revascularization of the European Society of Cardiology
(ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)
developed with the special contribution of the European Association of
Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac
Surg 2014;46: 517–92.
[12] Luckraz H, Giri R, Wrigley B, Hennessy A-M, Nicholas J, Nevill A. The use
of the RenalGuard system in cardiac surgery with cardiopulmonary-
bypass: a first in man prospective, observational, feasibility pilot study.
Open Heart BMJ 2017;4:e000669.
[13] Vives M, Hernandez A, Parramon F, Estanyol N, Pardina B, Mu~noz A
et al. Acute Kidney Injury after cardiac surgery: prevalence, impact and
management challenges. Int J Nephrol Renovasc Dis 2019;12:153–66.
[14] Mehta RH, Grab JD, O’Brien SM, Bridges CR, Gammie JS, Haan CK et al.;
STS National Cardiac Surgery Database Investigators. Bedside-tool for
predicting the risk of post-operative dialysis in patients undergoing car-
diac surgery. Circulation 2006;114:2208–16.
[15] Demirjian S, Schold JD, Navia J, Mastracci TM, Paganini EP, Yared JP
et al. Predictive models for acute kidney injury following cardiac surgery.
Am J Kidney Dis 2012;59:382–9.
[16] Johnston LE, Thiele RH, Hawkins RB, Downs EA, Jaeger JM, Brooks C
et al.; Virginia Interdisciplinary Cardiothoracic Outcomes Research
Center. Goal-directed resuscitation following cardiac surgery reduces
acute kidney injury: a quality initiative pre-post analysis. J Thorac
Cardiovasc Surg 2020;159:1868–77.
[17] Penk J, Gist KM, Wald EL, Kitzmiller L, Webb TN, Li Y et al. Furosemide
response predicts acute kidney injury in children after cardiac surgery. J
Thorac Cardiovasc Surg 2019;157:2444–51.
[18] Fakhari S, Bavil FM, Bilehjani E, Abolhasani S, Mirinazhad M, Naghipour
B. Prophylactic furosemide infusion decreasing early major postopera-
tive renal dysfunction in on-pump adult cardiac surgery: randomized
clinical trial. Res Rep Urol 2017;9:5–13.
[19] Mahesh B, Yim B, Robson D, Pillai R, Ratnatunga C, Pigott D. Does fur-
osemide prevent renal dysfunction in high-risk cardiac surgical patients?
Results of a double-blinded prospective randomised trial. Eur J
Cardiothorac Surg 2008;33:370–6.
[20] Kunt AT, Akgün S, Atalan N, Bitir N, Arsan S. Furosemide infusion pre-
vents the requirement of renal-replacement-therapy after cardiac sur-
gery. Anadolu Kardiyol Derg 2009;9:499–504.
[21] Lassnigg A, Donner E, Grubhofer G, Presterl E, Druml W, Hiesmayr M.
Lack of renoprotective effects of dopamine and furosemide during car-
diac surgery. J Am Soc Nephrol 2000;11:97–104.
[22] Aravindan N, Aravindan S, Riedel BJ, Weng HR, Shaw AD. Furosemide
prevents apoptosis and associated gene-expression in a rat model of
surgical ischemic acute renal failure. Ren Fail 2007;29:399–407.
[23] Kanakis M, Martens T, Muthialu N. Postoperative saline administration
following cardiac surgery: impact of high versus low-volume administra-
tion on acute kidney injury. J Thorac Dis 2019;11:S1150–2.
[24] Lim JY, Kang PJ, Jung SH, Choo SJ, Chung CH, Lee JW et al. Effect of
high- versus low-volume saline administration on acute kidney injury
after cardiac-surgery. J Thorac Dis 2018;10:6753–62.
[25] Hu J, Chen R, Liu S, Yu X, Zou J, Ding X. Global incidence and outcomes
of adult patients with acute kidney injury after cardiac-surgery: a
systematic review and meta-analysis. J Cardiothorac Vasc Anesth 2016;
30:82–9.
[26] Chew ST, Ng RR, Liu W, Chow KY, Ti LK. Acute kidney injury increases
the risk of end-stage-renal-disease after cardiac surgery in an Asian
population: a prospective cohort study. BMC Nephrol 2017;18:60.
[27] Lee S, Park S, Kang MW, Yoo HW, Han K, Kim Y et al. Post-discharge
long-term cardiovascular outcomes of intensive care unit survivors who
developed dialysis-requiring acute kidney injury after cardiac-surgery.
J Crit Care 2019;50:92–8.






/ejcts/advance-article/doi/10.1093/ejcts/ezaa395/6000632 by guest on 01 D
ecem
ber 2020
